Clinical trial · Interventional
A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)
A Phase II Efficacy Study of MK-4827 in Patients With Mantle Cell Lymphoma
NCT01244009CI-TRIAL-00024736withdrawnPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Sponsor decision
Summary
Brief summary (as posted)
This study will investigate the efficacy and safety of MK-4827 in participants with relapsed mantle cell lymphoma (MCL) and in a subset of participants with inactivation of the Ataxia-Telangiectasia Mutated (ATM) gene.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Mantle-Cell | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MK-4827 | Drug | Niraparib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- MK-4827
- description
- All Participants
- interventionNames
- Drug: MK-4827
Primary outcomes (1)
- measure
- Number of participants who have a complete response (CR) or partial response (PR) during the study
- timeFrame
- Tumor assessments will be performed every 9 weeks for the first year the participant is on treatment, every 12 weeks in year 2, and every 6 months in year 3 and beyond
Secondary outcomes (2)
- measure
- Number of Participants with adverse events
- timeFrame
- From the day of enrollment through 30 days after the last dose of study drug
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria : * Participant must have a diagnosis of MCL that has relapsed after at least one prior chemotherapy regimen or for which the participant has refused standard therapy * Participant has measureable disease defined by lymphadenopathy, organomegaly, bone marrow involvement and/or circulating lymphoma cells. At least one lesion must be \> 2 cm in the longest diameter and measurable in 2 perpendicular dimensions * Participant has a performance status of 0, 1, or 2 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale * Female participants of child-bearing potential agree to use two approved contraceptive methods or remain abstinent throughout the study * Male participants agree to use an adequate method of contraception throughout the study * Participant has no history of prior cancer except certain cervical, skin, or prostate cancers, or has undergone potentially curative therapy with no recurrence for five years, or is deemed at low risk for recurrence * Participant has not had any platelet or red blood cell transfusions or colony stimulating factor support during the month prior to treatment * Participant has a pre-study diagnostic formalin fixed paraffin-embedded tumor tissue sample available Exclusion Criteria : * Participant has had chemotherapy, radiotherapy, or biological therapy within 4 weeks of screening * Participant has a history of central nervous system (CNS) lymphoma * Participant requires the use of corticosteroids * Participant is pregnant, breastfeeding, or expecting to conceive or father children during the study * Participant is known to be human immunodeficiency virus (HIV)-positive * Participant has a history of Hepatitis B or C
References
Publications (0)
Data not yet available
No reference posted for this study.